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Background. Baloxavir marboxil (baloxavir) is a single-dose, oral antiinfluenza drug with a novel mechanism of action. We 
compared the incidence of hospitalization in patients treated with baloxavir vs neuraminidase inhibitors.
Methods. In this retrospective, observational, cohort study, we used real-world patient data extracted from a Japanese health 
insurance claims database. The enrollment period was 1 October 2018 to 17 April 2019. On day 1, eligible patients (N = 339 007) 
received baloxavir, oseltamivir, zanamivir, or laninamivir. Baseline characteristics were standardized using the inverse probability 
of treatment weighting method. The primary end point was the incidence of hospitalization (days 2–14). Secondary end points in-
cluded antibacterial use, secondary pneumonia, and additional antiinfluenza drug use.
Results. Compared with the baloxavir group, the incidence of hospitalization was greater in the oseltamivir group (risk ratio 
[RR] and 95% confidence interval [CI], 1.41 [1.00–2.00]; risk difference [RD] and 95% CI, 0.06 [.01–.12]) and zanamivir group (RR, 
1.85 [1.23–2.78]; RD, 0.11 [.02–.20]). Oseltamivir-treated patients were less likely to require antibacterials than baloxavir-treated 
patients (RR, 0.87 [.82–.91]). However, oseltamivir-treated patients were more likely to be hospitalized with antibacterials (RR, 1.70 
[1.21–2.38]) or antibacterial injection (RR, 1.67 [1.17–2.38]) than baloxavir-treated patients (post hoc analysis). Compared with 
baloxavir-treated patients, additional antiinfluenza drug use was greater in oseltamivir-, zanamivir-, and laninamivir-treated pa-
tients (RR, 1.51 [1.05–2.18], 2.84 [2.04–3.96], and 1.68 [1.35–2.10], respectively).
Conclusions. Baloxavir is an efficacious antiinfluenza treatment that may reduce hospitalization compared with oseltamivir and 
zanamivir.
clinical Trials Registration. University hospital Medical Information Network Clinical Trials Registry (UMIN000038159).
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Influenza is a contagious respiratory illness that ranges from 
mild to severe. Although most influenza infections resolve 
without treatment, they can lead to complications and result in 
hospitalization [1]. In Japan, 4 neuraminidase inhibitors (NAIs; 
oseltamivir, zanamivir, laninamivir, and peramivir) are ap-
proved for the treatment of influenza [1].
Baloxavir marboxil (baloxavir), an antiinfluenza drug with a 
novel mechanism of action (cap-dependent endonuclease inhib-
itor), was first approved in Japan [2]. In the trials in adults and 
adolescents with uncomplicated influenza, 1 day after trial reg-
imen initiation, a single dose of baloxavir significantly reduced 
the viral load compared with oseltamivir and placebo [3]. In a 
recent observational study of patients with influenza A, the du-
ration of fever was significantly shorter for baloxavir-treated pa-
tients compared with NAI-treated patients [4]. In a phase 3 trial 
in high-risk influenza patients, baloxavir significantly reduced 
the incidence of influenza-related complications compared with 
placebo [5]. Given the ability of baloxavir to significantly reduce 
the viral load compared with oseltamivir and to reduce the time 
to alleviation of fever compared with NAI treatment, baloxavir 
treatment in the real-world setting may provide a superior alter-
native for alleviating influenza symptoms and thus prevent the 
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Our aim in this retrospective, observational, cohort study, 
using data extracted from a health insurance claims database, 
was to examine the effect of baloxavir treatment in the real-
world setting on the incidence of hospitalization, antibacterial 
use, secondary pneumonia, and additional antiinfluenza drug 




In this population-based, active comparator, retrospective, 
cohort study, we used data from the JMDC health insurance 
claims database (JMDC Inc, Tokyo, Japan). The JMDC data-
base is an epidemiological receipt database that contains inpa-
tient, outpatient, and dispensing receipts received from health 
insurance associations, allowing for individual patient data to 
be tracked across multiple facilities. By April 2020, the cumu-
lative dataset consisted of 7.3 million individuals. The data 
extraction period was 1 April 2018 to 30 April 2019, which 
included the 2018–2019 influenza season. The study was con-
ducted in accordance with Ethical Guidelines for Medical and 
Health Research Involving Human Subjects. Informed written 
consent was not required because the study used deidentified 
data. 
Study Population
The study consisted of 4 influenza outpatient populations: those 
treated with baloxavir, oseltamivir, zanamivir, or laninamivir. 
The oseltamivir group was predefined as the primary compar-
ator group. Peramivir was not included as a comparator in this 
study as it is administered intravenously and would likely be 
selected under different circumstances from oral and inhalant 
antiinfluenza drugs.
For the study population, eligible patients were those whose 
first influenza diagnosis date (day 1, starting date of influenza 
medical care) was within the enrollment period (1 October 
2018 to 17 April 2019), who were continuously registered in the 
database ≥6 months before day 1, and who received baloxavir, 
oseltamivir, zanamivir, or laninamivir on day 1. Influenza virus 
infection was defined by International Statistical Classification 
of Diseases and Related Health Problems, 10th Revision (ICD-
10) codes J09–J11. Patients were excluded if they were hospital-
ized in the last 90 days before day 1 or received antibacterials 
(European Pharmaceutical Market Research Association 
[EphMRA] Anatomical Therapeutic Chemical [ATC] code J01) 
on day 1 or in the last 90 days before day 1 or were diagnosed 
with pneumonia (ICD-10 codes J12–J18) within 3 months be-
fore day 1 (including day 1). This was to exclude the possibility 
that hospitalization, antibacterial administration, or pneu-
monia was due to a chronic illness (or disease other than influ-
enza) as much as possible. Patients aged <1 year were excluded 
because baloxavir is not indicated for patients who weigh 
<10 kg. Patients who died on day 1 were also excluded. To en-
sure that the outcomes measured in this study were attributable 
to a single agent, patients who received >1 antiinfluenza drug 
(baloxavir, oseltamivir, zanamivir, laninamivir, or peramivir) on 
day 1 were excluded.
Outcome Measures
The primary end point was the incidence of hospitalization 
during days 2−14. Secondary end points included the occur-
rence of antibacterial (oral and/or injectable) administration 
(EphMRA-ATC code J01), antibacterial injection (EphMRA-
ATC code J01; dosage form, injection drug), pneumonia (ICD-
10 codes J12–J18), and additional antiinfluenza drug use (any 
antiinfluenza drug different from the one received on day 
1)  during days 2−14. The overall incidence of the secondary 
end points (prespecified analysis) and the incidence of sec-
ondary end points with hospitalization (post hoc analysis) were 
determined.
Statistical Analyses
The analysis population included all patients who met the el-
igibility criteria and excluded those who were hospitalized on 
day 1 (Figure  1). The comparison groups were the baloxavir 
group (patients who received oral baloxavir on day 1) and each 
NAI group (patients who received oral oseltamivir, inhaled 
zanamivir, or inhaled laninamivir on day 1). Comparisons were 
made between the standardized baloxavir group and the stand-
ardized NAI groups (oseltamivir [main comparison group], 
zanamivir, or laninamivir). Risk ratios (RRs) and risk differ-
ences (RDs) were calculated as the incidence of the severity end 
point in the NAI group divided by, or minus, the incidence in 
the baloxavir group, respectively. The 95% confidence intervals 
(CIs) for both the RRs and RDs after standardization of each 
group in the comparison pair were determined. When the RR 
and RD 95% CIs did not contain 1 and 0, respectively, differ-
ences between groups were considered statistically significant 
(2-sided significance level, 0.05).
To standardize the patient baseline demographic and clin-
ical characteristics between the baloxavir group and each NAI 
group, the propensity score was calculated and the inverse prob-
ability of treatment weighting (IPTW) method was applied. To 
calculate propensity score, a logistic regression analysis was 
performed using the baloxavir group as the response variable 
(1 for the baloxavir group, 0 otherwise) and the patient baseline 
characteristics (covariates) as the explanatory variable. The pro-
pensity score calculated as the predicted probability (P) from 
logistic regression analysis for the baloxavir group for each pa-
tient was used as the weight (ie, 1/P for the baloxavir group, 1/
(1 – P) for each NAI group).
Covariates (patient baseline characteristics) used to calculate 
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severity [6]. Patient age was categorized as following: 1 to <2, ≥2 
to <5, ≥5 to <18, ≥18 to <65, and ≥65 years. The age categories 
were consistent with those most widely used [7]. Comorbidities 
were diagnosed by ICD-10 code (a receipt corresponding to 
the ICD-10 code was required within the 6  months prior to 
the month of day 1 or, if the receipt occurred in the month of 
day 1, then on a day prior to day 1) or by the administration of 
disease-related medication (corresponding drug was adminis-
tered within 180 days before day 1). Covariates included age, 
gender, influenza virus type (ICD-10 codes J09–J11), and the 
presence or absence of the following (disease diagnosis was 
defined by the administration of disease-related medication; 
corresponding drug was administered within 180  days be-
fore day 1 [excluding day  1]): steroid administration (World 
Health Organization [WHO] ATC code H02), dialysis (defined 
by the presence/absence of a dialysis-related medical care ac-
tivity), respiratory coinfection (ICD-10 codes J00–J06, J2) ex-
cluding pneumonia, asthma (corresponding drug WHO-ATC 
code R03), diabetes (corresponding drug WHO-ATC code 
A10), chronic obstructive lung disease (ICD-10 codes J41–J44), 
cardiovascular disease (ICD-10 codes I20–I25, Q20–Q28), 
cerebrovascular disease (ICD-10 codes I60–I69), mental ill-
ness including dementia (ICD-10 codes F00–F99), neurolog-
ical disease (ICD-10 codes G00–G99), anemia (ICD-10 codes 
D50–D59, D60–D64), immune deficiency (ICD-10 codes D80–
D89), liver disease (ICD-10 codes K70–K77), and malignant 
tumor (ICD-10 codes D00–D09, C00–C97).
The standardized mean difference (SMD) between the com-
parison groups was calculated for each patient baseline char-
acteristic (by giving 1 if appropriate for the category, 0 for 
otherwise). Sensitivity analyses of the primary and secondary 
end points were conducted for the comparison of 2 treatment 
groups and included patients with an influenza virus diagnostic 
test on day 1 (data not shown).
Missing values were not replaced and multiplicity was not ad-
justed for repeated tests. All analyses were conducted using SAS 
version 9.4 (SAS Institute Inc, Cary, NC).
RESULTS
Demographic and Baseline Clinical Characteristics
During the 2018–2019 influenza season, 7 320 512 individ-
uals were recorded in the JMDC claims database; of these, 
339 007 patients met the eligibility criteria for the study anal-
ysis population (Figure 1). The most common antiinfluenza 
drug was baloxavir (N = 146  192), followed by oseltamivir 
(N = 92  700), laninamivir (N = 81  438), and zanamivir 
(N = 18  677). Table  1 summarizes the unadjusted patient 
Figure 1. Flow chart of the study cohort. aPatients could be excluded for ≥1 reason. bDate of earliest diagnosis of influenza virus infection. Abbreviations: BXM, baloxavir 
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baseline demographic and clinical characteristics for the 
study population.
The proportion of patients aged <5 years was higher in the 
oseltamivir group compared with the other 3 treatment cohorts. 
For those patients whose influenza type could be determined, 
most were infected with influenza A. Approximately half of the 
patients in the study population had a respiratory coinfection, 
and the proportion of patients with asthma in the oseltamivir 
group was approximately twice that in the baloxavir group. 
Baseline demographic and clinical characteristics of patients 
after standardization using the IPTW method were well bal-
anced across the treatment groups (SMD were all <0.1; Table 2).
Hospitalization Incidence
The incidence of hospitalization was greater in the oseltamivir 
group than in the baloxavir group, with no statistically signif-
icant RR of 1.41 (95% CI, 1.00–2.00) and a statistically signif-
icant RD of 0.06 (95% CI, .01–.12; Figure  2). The incidence 
of hospitalization was statistically significantly greater in the 
zanamivir group than in the baloxavir group, with a significant 
RR of 1.85 (95% CI, 1.23–2.78) and significant RD of 0.11 (95% 
CI, .02–.20). No significant difference in the incidence of hos-
pitalization between the laninamivir and baloxavir groups was 
observed.
Antibacterial Administration, Pneumonia, and Additional Antiinfluenza 
Drug Use
Overall, patients in the oseltamivir group had a reduced risk 
of requiring antibacterial administration than patients in 
the baloxavir group (Figure  3A). In contrast, patients in the 
oseltamivir group had a greater risk of requiring additional 
antiinfluenza drugs than patients in the baloxavir group 
(Figure  3A). Patients in the zanamivir group had a reduced 
risk of pneumonia compared with patients in the baloxavir 
group (Figure  3B). In the zanamivir and laninamivir groups, 
patients were more likely to require additional antiinfluenza 
drugs compared with patients in the baloxavir group (Figure 3B 
and 3C). Details of additional antiinfluenza drug use and an-
tibacterial administration are listed in Supplementary Tables 1 
and 2. Baloxavir and peramivir were most frequently used as 
additional antiinfluenza drugs, while macrolides and cephalo-
sporins were most frequently used as antibacterial drugs.
As post hoc analysis, the incidence of secondary end 
points with hospitalization were assessed. Patients treated 
with oseltamivir had a significantly greater risk of requiring 
hospitalization with antibacterial administration and hos-
pitalization with antibacterial injection compared with 
baloxavir-treated patients (Figure 4A). Patients treated with 
zanamivir had a significantly greater risk of requiring hos-
pitalization with antibacterial administration compared 
with baloxavir-treated patients (Figure  4B). Patients in the 
laninamivir group were 1.38 times more likely to require 
hospitalization with antibacterial administration than the 
baloxavir group, although this risk was not significantly dif-
ferent (95% CI, 1.00–1.91; Figure 4C).
DISCUSSION
To our knowledge, this is the first study to use population-based, 
real-world patient data to investigate the incidence of hospitali-
zation after outpatient influenza treatment with baloxavir com-
pared with NAIs. The incidence of hospitalization was lower in 
baloxavir-treated patients than in oseltamivir-treated patients 
with no statistically significant RR and a statistically significant 
RD while that in baloxavir-treated patients was lower compared 
with zanamivir-treated patients with statistically significant 
Figure 2. Risk ratio and risk difference of hospitalization. aData were standardized using the inverse probability of treatment weighting method; the risk ratio was cal-
culated using the exposed (baloxavir) group as the denominator and the neuraminidase inhibitor (NAI) group (oseltamivir, zanamivir, or laninamivir) as the numerator. Risk 
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Figure 3. Risk ratio and risk difference of antibacterial administration (oral and/or injectable), injectable antibacterial use, pneumonia, and additional antiinfluenza drug 
use regardless of hospitalization. (A) Oseltamivir vs baloxavir. (B) Zanamivir vs baloxavir. (C) Laninamivir vs baloxavir. aData were standardized using the inverse probability of 
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RR/RD. These results suggest that baloxavir reduces the risk of 
hospitalization compared with oseltamivir or zanamivir.
In this study, the administration of antibacterial treatment 
(both oral and injectable) upon hospitalization was significantly 
reduced for baloxavir-treated patients compared with oseltamivir-
treated patients. However, the incidence of antibacterial admin-
istration regardless of hospitalization was significantly higher 
with baloxavir than with oseltamivir. One possible explanation 
for this discrepancy is that the outpatient administration of anti-
bacterial drugs may have contributed to the reduced incidence of 
hospitalization in the baloxavir group. However, for all cohorts, 
the incidence of hospitalization was increased in those patients 
who received outpatient antibacterials (Supplementary Table 3). 
This is not surprising as the requirement for antibacterials indi-
cates that a patient may be experiencing a secondary infection, 
which can lead to complications that require hospitalization. 
These results suggest that the lower hospitalization incidence for 
baloxavir-treated patients compared with oseltamivir-treated pa-
tients was not due to the higher antibacterial administration rate. 
Studies have shown that patients aged ≥16 years hospitalized with 
influenza have a high and persistent viral load [8, 9]. Although 
the study results from patients aged ≥16 years may not always be 
applicable to all age groups, the lower incidence of hospitalization 
observed for the baloxavir group in this study compared with the 
oseltamivir group may be attributable to baloxavir’s ability to re-
duce the viral load more rapidly than oseltamivir [3]. This is also 
consistent with our observation that the incidence of additional 
administration of antiinfluenza drugs was significantly lower 
for the baloxavir group compared with the oseltamivir group 
(Figure 3A). The reason why the baloxavir group had a higher in-
cidence of antibacterial administration is not known and is a lim-
itation. As possible reasons, since diphasic fever is often observed 
in young children with influenza [10, 11], oral antibacterials, 
which might be prescribed for inadequate reasons in Japan [12], 
might have been more frequently prescribed for baloxavir-treated 
outpatients due to its single-dose administration and concerns 
about development of secondary infections such as bacterial in-
fection or baloxavir-insensitive strains in pediatric patients [13].
Baloxavir compared favorably with both inhaled NAIs 
(zanamivir and laninamivir), although direct comparisons are 
limited because of possible confounding due to the different 
routes of administration. In comparison with the zanamivir 
group, baloxavir-treated outpatients had a reduced incidence of 
hospitalization and hospitalization that required antibacterials 
(oral/injectable). However, the baloxavir group had an in-
creased risk of pneumonia compared with the zanamivir group. 
Physicians may have been less likely to prescribe zanamivir, 
which requires 10 inhalations over 5  days, to patients with 
compromised lung function; such patients are also more likely 
to develop pneumonia. Although we adjusted for underlying pa-
tient baseline characteristics, including chronic respiratory dis-
eases, the condition of some patients with compromised lung 
function may not have been captured in the database. Therefore, 
we have not adjusted for this condition in those patients, and it 
was possible that those patients were less likely to be prescribed 
zanamivir. Nevertheless, we are unable to determine the reason 
for the difference in pneumonia incidence. Both zanamivir- and 
laninamivir-treated patients in this study were more likely to re-
quire additional antiinfluenza drugs than baloxavir-treated pa-
tients. The additional antiinfluenza treatments may have been 
prescribed if the attending physician had concerns that the in-
haled formulation was not properly inhaled, for example, in chil-
dren [14, 15], or if a patient’s symptoms had not improved [16]. 
Analysis of data from a double-blind, randomized, clinical trial 
indicated that nonpersistence with influenza medication was 
greater for inhaled medication compared with oral medication 
(hazard ratio, 1.23; P = .043) [17]. In Japan, a survey of adherence 
to oseltamivir therapy revealed that 21% of patients discontinued 
oseltamivir, with patients revealing that a shorter treatment plan 
would be preferred [18]. In the current study, treatment ad-
herence was not examined, which is a limitation of the study. 
However, baloxavir treatment consists of a single oral dose, and 
therefore concerns of nonadherence to this antiinfluenza therapy, 
in particular in response to adverse side effects, are not relevant.
Extracting data from the health insurance claims database 
allowed us to compare the incidence of hospitalization asso-
ciated with multiple antiinfluenza drugs in real-world patient 
data with a sample size >330  000. However, we acknowledge 
that oseltamivir, given its oral route of administration, was the 
only true active comparator for baloxavir. This study was fur-
ther strengthened by using the IPTW method as we were able to 
adjust for the differences in treatment choice between patients 
based on demographics, influenza type, and the presence of 
other factors related to influenza severity.
Several limitations arose from using data from the health 
insurance claims database. The proportion of elderly patients 
(aged ≥65 years) in the database is low (approximately 1% [19]) 
because retired individuals no longer belong to an employer-
based health insurance association; therefore, the database is not 
representative of the aging population (28% are aged ≥65 years 
[20]). In addition, the number of patients aged <5 years treated 
with baloxavir, laninamivir, or zanamivir is also limited com-
pared with those treated with oseltamivir. Therefore, our study 
results may not be applicable to this population. Receipt infor-
mation in the database does not include information on the 
period from the onset of influenza to the start of treatment, 
zanamivir, or laninamivir) as the numerator. Risk difference was the incidence of the outcome end point in the NAI group minus the incidence in the baloxavir group. bBaloxavir, 
N = 146  192; oseltamivir, N = 92  700. cBaloxavir, N = 240  341.4; oseltamivir, N = 238  657.8. dBaloxavir, N = 146  192; zanamivir, N = 18  677. eBaloxavir, N = 164  892.3; 
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Figure 4. Risk ratio and risk difference of antibacterial administration (oral and/or injectable), injectable antibacterial use, pneumonia, and additional antiinfluenza drug 
use with hospitalization. (A) Oseltamivir vs baloxavir. (B) Zanamivir vs baloxavir. (C) Laninamivir vs baloxavir. aData were standardized using the inverse probability of treat-
ment weighting method; the risk ratio was calculated using the exposed (baloxavir) group as the denominator and the neuraminidase inhibitor (NAI) group (oseltamivir, 
zanamivir, or laninamivir) as the numerator. Risk difference was the incidence of the outcome end point in the NAI group minus the incidence in the baloxavir group. bBaloxavir, 
N = 146  192; oseltamivir, N = 92  700. cBaloxavir, N = 240  341.4; oseltamivir, N = 238  657.8. dBaloxavir, N = 146  192; zanamivir, N = 18  677. eBaloxavir, N = 164  892.3; 
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temperature data, and findings on influenza symptoms, so se-
verity of influenza symptoms at the start of treatment is un-
known. The accuracy and the severity of the diagnosis of the 
covariates used to calculate the propensity score are unknown. 
Similarly, the accuracy and the severity of the diagnosis of pneu-
monia, a secondary outcome measure, were also unknown. As 
this was an observational study, other unmeasured confounding 
factors may have existed. Also, although significant differences 
can be identified in observational studies of large datasets, it is 
very difficult to verify causal relationships. Additional studies 
to determine why hospitalization incidence was lower in the 
baloxavir group are required. Finally, the observational period 
for this study covered the 2018–2019 influenza season when 
both influenza A/H1N1 and A/H3N2 were the major influenza 
types; therefore, data for influenza B were limited.
In conclusion, the results of this study using real-world 
influenza patient data indicate that a single oral dose of 
baloxavir may reduce hospitalization compared with NAI 
treatment and provides an alternative antiinfluenza treat-
ment option.
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